Antibody-drug conjugate · Cytotoxic, directed at MUC16 (mucin-16, CA-125) (MUC16) · developed by Whitehawk Therapeutics
HWK-016 is an antibody-drug conjugate that targets MUC16 (mucin-16). It is being studied in platinum-resistant ovarian cancer and endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07470853 | Phase 1 | PROC | Recruiting | WHWK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial CancerPlatinum Resistant Ovarian CancerPROC
Updated Nov 1, 2026. Something wrong or missing? Report it on the WHWK page.
See WHWK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
WHWK catalysts and pipeline →